Inmune Bio Inc.
INMB· Nasdaq
Released Aug 7, 2025, after the close
10-Q filed Aug 7, 2025, 38 days after period end · 0001213900-25-073077
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $46.00K | $16.00K |
| Net Income | -$24.46M | -$9.75M | -$6.50M | -$6.84M |
| EPS Diluted |
Inmune Bio Inc. · CIK 1711754 · Engraved from SEC EDGAR
| -$1.05 |
| -$0.50 |
| -$0.36 |
| -$0.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.